华特达因(000915)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

000915 华特达因

已收盘 01-14 15:00:00

{"stockData":{"symbol":"000915","market":"SZ","secType":"STK","nameCN":"华特达因","latestPrice":33.07,"timestamp":1768374198000,"preClose":32.93,"halted":0,"volume":5281101,"delay":0,"changeRate":0.0043,"floatShares":234000000,"shares":234000000,"eps":2.3823,"marketStatus":"已收盘","change":0.14,"latestTime":"01-14 15:00:00","open":32.93,"high":33.28,"low":32.76,"amount":174000000,"amplitude":0.0158,"askPrice":33.07,"askSize":23,"bidPrice":33.06,"bidSize":31,"shortable":0,"etf":0,"ttmEps":2.3823,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768440600000},"marketStatusCode":5,"adr":0,"adjPreClose":32.93,"symbolType":"stock","openAndCloseTimeList":[[1768354200000,1768361400000],[1768366800000,1768374000000]],"highLimit":36.22,"lowLimit":29.64,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":234331485,"isCdr":false,"pbRate":2.71,"roa":"--","peRate":13.881543,"roe":"13.79%","epsLYR":2.2,"committee":0.105263,"marketValue":7749000000,"turnoverRate":0.0226,"status":0,"floatMarketCap":7744000000},"requestUrl":"/m/hq/s/000915","defaultTab":"news","newsList":[{"id":"2601801869","title":"华特达因（000915）披露子公司达因药业获得药品注册证书，1月7日股价下跌1.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601801869","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601801869?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:28","pubTimestamp":1767796099,"startTime":"0","endTime":"0","summary":"截至2026年1月7日收盘，华特达因报收于33.47元，较前一交易日下跌1.01%，最新总市值为78.43亿元。该股当日开盘33.81元，最高33.88元，最低33.41元，成交额达1.04亿元，换手率为1.32%。公司近日发布公告称，其子公司山东达因海洋生物制药股份有限公司收到国家药品监督管理局颁发的盐酸可乐定缓释片《药品注册证书》。同时提示，药品未来的销售情况将受到医药行业政策、招标采购及市场环境等因素影响，存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700039010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0122","BK0175","BK0239","BK0186","000915","BK0188"],"gpt_icon":0},{"id":"2601201858","title":"华特达因(000915.SZ)子公司取得一项药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2601201858","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601201858?lang=zh_cn&edition=full","pubTime":"2026-01-07 15:54","pubTimestamp":1767772447,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华特达因(000915.SZ)公告，公司的子公司山东达因海洋生物制药股份有限公司(简称达因药业)收到国家药品监督管理局颁发的《药品注册证书》，药品名称为：盐酸可乐定缓释片。本品用于单独或辅助中枢兴奋药治疗6-17岁儿童和青少年的注意缺陷多动障碍(ADHD)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389787.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0122","000915","BK0188","BK0186","BK0239","BK0175"],"gpt_icon":0},{"id":"2592026961","title":"华特达因：Mumheart液体钙镁锌饮亮相进博会","url":"https://stock-news.laohu8.com/highlight/detail?id=2592026961","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592026961?lang=zh_cn&edition=full","pubTime":"2025-12-17 15:06","pubTimestamp":1765955186,"startTime":"0","endTime":"0","summary":"证券之星消息，华特达因12月17日在投资者关系平台上答复投资者关心的问题。Mumheart品牌跨境产品当前销售额、复购率如何？“Mumheart”液体钙镁锌饮采用品牌专研的“DYNE-KidHealthT+量身定制超效吸收”技术，一袋补充钙、镁、锌等7种关键营养。目前，该品牌已在第八届进博会上亮相，公司正在为产品上市做相关筹备工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700018287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0188","BK0122","BK0239","000915","BK0186"],"gpt_icon":0},{"id":"2588854880","title":"华特达因：小儿布洛芬栓和伊可新AD剂市场需求稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=2588854880","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588854880?lang=zh_cn&edition=full","pubTime":"2025-12-02 11:37","pubTimestamp":1764646651,"startTime":"0","endTime":"0","summary":"证券之星消息，华特达因(000915)12月02日在投资者关系平台上答复投资者关心的问题。投资者提问：流感季到来，公司的抗流感药物，和伊可新AD剂，销量有没有增加？华特达因回复：您好！公司会根据市场需求灵活调整生产及销售，目前公司的小儿布洛芬栓和伊可新AD剂等市场需求稳定。公司会持续关注市场动态，公司现有生产完全能够满足市场对各类产品的需求。感谢您的关注!以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200013043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0122","000915","BK0188","BK0239","BK0175","BK0186"],"gpt_icon":0},{"id":"2588085501","title":"华特达因：褪黑素颗粒预计2026年初上市销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2588085501","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588085501?lang=zh_cn&edition=full","pubTime":"2025-12-02 11:34","pubTimestamp":1764646443,"startTime":"0","endTime":"0","summary":"证券之星消息，华特达因(000915)12月02日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，褪黑素产品预计年底前能否上市？近期股价下跌是否跟褪黑素产品未能上市有关？华特达因回复：您好！公司代理的褪黑素颗粒产品预计将于2026年初正式实现上市销售，目前正积极的推进曼乐静产品上市的相关准备工作。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200012788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0122","000915","BK0188","BK0186","BK0239","BK0175"],"gpt_icon":0},{"id":"2584769829","title":"股市必读：华特达因（000915）11月14日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2584769829","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584769829?lang=zh_cn&edition=full","pubTime":"2025-11-17 02:27","pubTimestamp":1763317633,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，华特达因报收于35.6元，上涨0.56%，换手率2.34%，成交量5.48万手，成交额1.96亿元。按照持股比例计算，归属于上市公司股东的净利润为4.08亿元。公司代理的褪黑素产品目前尚未实现上市销售，目前正积极的推进曼乐静产品上市的相关准备工作。投资者： 尊敬的董秘，您好，贵司25年3季度扣非利润不到7千万，环比一、二季度均下降50%左右。今年三季度利润却再度大幅下滑，营收也下降1至2亿，想请问董秘是什么原因造成的。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700000871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000915","BK0175","BK0186","BK0188","BK0239","BK0122"],"gpt_icon":0},{"id":"2583527550","title":"华特达因：代理的褪黑素产品尚未实现上市销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2583527550","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583527550?lang=zh_cn&edition=full","pubTime":"2025-11-14 15:06","pubTimestamp":1763103978,"startTime":"0","endTime":"0","summary":"证券之星消息，华特达因(000915)11月14日在投资者关系平台上答复投资者关心的问题。投资者提问：公司代理的褪黑素产品上市没有销售的怎么样？华特达因回复：您好！公司代理的褪黑素产品目前尚未实现上市销售，目前正积极的推进曼乐静产品上市的相关准备工作。谢谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400018898.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000915","BK0122","BK0175","BK0186","BK0188","BK0239"],"gpt_icon":0},{"id":"2583528672","title":"华特达因：医药业务净利润7.57亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583528672","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583528672?lang=zh_cn&edition=full","pubTime":"2025-11-14 11:37","pubTimestamp":1763091437,"startTime":"0","endTime":"0","summary":"证券之星消息，华特达因(000915)11月14日在投资者关系平台上答复投资者关心的问题。投资者提问：您好贵公司三季度报告中，表述医药业务净利润7.57亿，但是实际是4.08亿，请问其中少去的2.5亿是哪个行业亏损造成的？谢谢华特达因回复：您好！公司医药业务主要由控股子公司达因药业及达因康健、达因高科运营。2025年前三季度，该板块实现净利润7.57亿元。按照持股比例计算，归属于上市公司股东的净利润为4.08亿元。谢谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400014953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000915","09939","159938"],"gpt_icon":0},{"id":"2583528660","title":"华特达因：前三季度扣非后归母净利润同比增长超15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583528660","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583528660?lang=zh_cn&edition=full","pubTime":"2025-11-14 11:37","pubTimestamp":1763091436,"startTime":"0","endTime":"0","summary":"投资者提问：尊敬的董秘，您好，贵司25年3季度扣非利润不到7千万，环比一、二季度均下降50%左右。今年三季度利润却再度大幅下滑，营收也下降1至2亿，想请问董秘是什么原因造成的。在行业内企业总体面临巨大的经营压力的情况下，公司聚焦并加强主业经营管理，加大市场营销力度，提高产品销售收入，努力实现了前三季度扣非后归母净利润超15%的同比增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400014951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000915"],"gpt_icon":0},{"id":"2583528981","title":"华特达因：拓展“中大童”市场应对出生率下降","url":"https://stock-news.laohu8.com/highlight/detail?id=2583528981","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583528981?lang=zh_cn&edition=full","pubTime":"2025-11-14 11:37","pubTimestamp":1763091435,"startTime":"0","endTime":"0","summary":"证券之星消息，华特达因11月14日在投资者关系平台上答复投资者关心的问题。近年来人口出生率下降，达因药业遵循循证医学原则，依据专家共识等科学指南，宣传普及并拓展维生素AD等产品的“中大童”市场，同时基于儿童临床需要和健康需求，通过研发和合作等开展医药产品的品类延伸和营养健康产品的品牌延伸，以不断丰富的多元化儿童医药健康产品矩阵，推动公司产品销售和业绩发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400014950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0122","BK0186","BK0188","BK0239","BK0175","000915"],"gpt_icon":0},{"id":"2583286765","title":"华特达因：小儿布洛芬栓可用于儿童流感发热","url":"https://stock-news.laohu8.com/highlight/detail?id=2583286765","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583286765?lang=zh_cn&edition=full","pubTime":"2025-11-14 11:37","pubTimestamp":1763091434,"startTime":"0","endTime":"0","summary":"证券之星消息，华特达因(000915)11月14日在投资者关系平台上答复投资者关心的问题。投资者提问：近期儿童流感这么严重公司有这方面的药吗？华特达因回复：您好！目前公司产品小儿布洛芬栓可用于儿童普通感冒和流行性感冒引起的发热。另外公司维生素AD滴剂、益生菌等产品有助于增强儿童免疫力。谢谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400014947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0122","BK0186","BK0239","BK0175","000915"],"gpt_icon":0},{"id":"2579699274","title":"股市必读：华特达因（000915）10月28日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2579699274","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579699274?lang=zh_cn&edition=full","pubTime":"2025-10-29 04:28","pubTimestamp":1761683294,"startTime":"0","endTime":"0","summary":"截至2025年10月28日收盘，华特达因报收于33.2元，下跌0.54%，换手率1.6%，成交量3.76万手，成交额1.26亿元。董秘最新回复投资者： 尊敬的董秘先生，这是第五次就要咨询贵司同一个问题，望正面回复。当日关注点来自交易信息汇总：10月28日主力资金净流出1365.89万元，散户资金净流入1604.16万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900007574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0122","BK0186","BK0175","000915","BK0188","BK0239"],"gpt_icon":0},{"id":"2578849529","title":"华特达因：无长效胰岛素类似物研发合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2578849529","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578849529?lang=zh_cn&edition=full","pubTime":"2025-10-28 15:06","pubTimestamp":1761635183,"startTime":"0","endTime":"0","summary":"证券之星消息，华特达因(000915)10月28日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘先生，这是第五次就要咨询贵司同一个问题，望正面回复。子公司达因药业和“中国医学科学院药生所”战略合作协议的主要方向和产品当中，有合作部分是长效胰岛素类似物产品，明年要进入临床？华特达因回复：您好，公司及子公司目前没有您提到的长效胰岛素类似物产品的研发和合作，谢谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800021481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0175","BK0188","000915","BK0122","BK0239"],"gpt_icon":0},{"id":"2578984951","title":"华特达因：合同负债增加因预收货款增多","url":"https://stock-news.laohu8.com/highlight/detail?id=2578984951","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578984951?lang=zh_cn&edition=full","pubTime":"2025-10-28 15:06","pubTimestamp":1761635181,"startTime":"0","endTime":"0","summary":"证券之星消息，华特达因10月28日在投资者关系平台上答复投资者关心的问题。投资者提问：您好很关注贵公司发展，贵公司第三季度报告中，合同负债2亿多，销售费用1.6亿，这两个数值，环比同比都大幅增加，请解释下原因，是代理褪黑素产品的前期投入和收取的下游进货资金么？谢谢华特达因回复：您好，公司第三季度报告中合同负债的增加主要因预收货款增加等因素。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800021477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0239","BK0188","000915","BK0175","BK0122"],"gpt_icon":0},{"id":"2578520236","title":"股市必读：华特达因(000915)股东户数2.76万户，较上期增加7.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578520236","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578520236?lang=zh_cn&edition=full","pubTime":"2025-10-27 04:20","pubTimestamp":1761510017,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，华特达因报收于32.83元，上涨0.03%，换手率1.5%，成交量3.52万手，成交额1.16亿元。交易信息汇总资金流向10月24日主力资金净流入583.91万元；游资资金净流出199.95万元；散户资金净流出383.96万元。股本股东变化股东户数变动近日华特达因披露，截至2025年9月30日公司股东户数为2.76万户，较6月30日增加1963.0户，增幅为7.66%。户均持股数量由上期的9141.0股减少至8491.0股，户均持股市值为26.58万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700001174.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0239","BK0186","BK0188","BK0122","000915"],"gpt_icon":0},{"id":"2577966705","title":"华特达因(000915.SZ)发布前三季度业绩，归母净利润4.08亿元，同比增长11.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577966705","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577966705?lang=zh_cn&edition=full","pubTime":"2025-10-24 17:01","pubTimestamp":1761296497,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华特达因(000915.SZ)发布2025年三季度报告，前三季度，公司实现营业收入16.03亿元，同比增长16.30%。归属于上市公司股东的净利润4.08亿元，同比增长11.67%。归属于上市公司股东的扣除非经常性损益的净利润4亿元，同比增长15.80%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1359378.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华特达因(000915.SZ)发布前三季度业绩，归母净利润4.08亿元，同比增长11.67%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000915"],"gpt_icon":0},{"id":"2575284977","title":"股市必读：华特达因（000915）10月13日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2575284977","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575284977?lang=zh_cn&edition=full","pubTime":"2025-10-14 02:28","pubTimestamp":1760380094,"startTime":"0","endTime":"0","summary":"截至2025年10月13日收盘，华特达因报收于32.26元，下跌1.25%，换手率1.4%，成交量3.27万手，成交额1.06亿元。董秘最新回复投资者： 请问贵公司除了大笔分红外有没有其他的方式，提升投资者的信心。最后，公司通过高比例现金分红的方式，与股东共享公司发展成果。交易信息汇总资金流向10月13日主力资金净流出524.21万元；游资资金净流入772.43万元；散户资金净流出248.22万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101400027430.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0122","BK0186","BK0188","000915","BK0239"],"gpt_icon":0},{"id":"2575208964","title":"华特达因：聚焦医药主业提升经营业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2575208964","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575208964?lang=zh_cn&edition=full","pubTime":"2025-10-13 15:05","pubTimestamp":1760339124,"startTime":"0","endTime":"0","summary":"证券之星消息，华特达因10月13日在投资者关系平台上答复投资者关心的问题。最后，公司通过高比例现金分红的方式，与股东共享公司发展成果。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101300014326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000915","BK0175","BK1161","BK1574","BK0188","BK1515","09939","BK0122","BK0186","159938","BK0239"],"gpt_icon":0},{"id":"2574177550","title":"华特达因（000915）披露2025年中期分红派息实施公告，10月10日股价上涨2.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574177550","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574177550?lang=zh_cn&edition=full","pubTime":"2025-10-10 22:30","pubTimestamp":1760106625,"startTime":"0","endTime":"0","summary":"公司近日发布公告称，山东华特达因健康股份有限公司将实施2025年中期分红派息。本次权益分派股权登记日为2025年10月16日，除权除息日为2025年10月17日。分红对象为截至股权登记日在中国结算深圳分公司登记在册的全体股东。A股股东现金红利由中国结算深圳分公司代派，于2025年10月17日划入股东资金账户；山东华特控股集团有限公司的现金红利由公司自行派发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101000039334.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0122","BK0188","BK0175","BK0239","BK0186","000915"],"gpt_icon":0},{"id":"2570963010","title":"股市必读：华特达因（000915）9月25日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2570963010","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570963010?lang=zh_cn&edition=full","pubTime":"2025-09-26 01:19","pubTimestamp":1758820752,"startTime":"0","endTime":"0","summary":"截至2025年9月25日收盘，华特达因报收于31.69元，下跌1.03%，换手率0.89%，成交量2.09万手，成交额6650.95万元。董秘最新回复投资者： 何时发放2025年中期股息董秘： 您好！公司暂未有回购计划。卧龙学校目前已停止招生办学，公司正积极通过司法等途径解决卧龙学校涉及的资产被沂南县设立的三所公办学校占用问题。当日关注点来自交易信息汇总：9月25日主力资金净流出127.03万元，散户资金净流入448.8万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092600000582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0186","BK0175","000915","BK0122","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768378530383,"stockEarnings":[{"period":"1week","weight":-0.026},{"period":"1month","weight":-0.0027},{"period":"3month","weight":0.0241},{"period":"6month","weight":0.0008},{"period":"1year","weight":0.3272},{"period":"ytd","weight":-0.0033}],"compareEarnings":[{"period":"1week","weight":0.0135},{"period":"1month","weight":0.0641},{"period":"3month","weight":0.0579},{"period":"6month","weight":0.1768},{"period":"1year","weight":0.3094},{"period":"ytd","weight":0.0428}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东华特达因健康股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"27598人(较上一季度增加7.66%)","perCapita":"8485股","listingDate":"1999-06-09","address":"山东省临沂市沂南县县城振兴路6号","registeredCapital":"23433万元","survey":"　　山东华特达因健康股份有限公司的主营业务是儿童医药和健康产品的研发、生产和销售业务。公司的主要产品是儿童药品、营养/保健食品、儿童健康用品。","listedPrice":4.68},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华特达因(000915)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华特达因(000915)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华特达因,000915,华特达因股票,华特达因股票老虎,华特达因股票老虎国际,华特达因行情,华特达因股票行情,华特达因股价,华特达因股市,华特达因股票价格,华特达因股票交易,华特达因股票购买,华特达因股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华特达因(000915)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华特达因(000915)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}